ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 4740

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

2 sessions
ACC.24 Late-breaking Science Wrap Up Watch now
What's Hot at ACC.24? Late-breaking Science Preview Watch now

Part 2

Late-Breaker Discussion Series

Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.  

4 sessions
Late-Breaker Discussion: The EMPACT-MI Trial Watch now
Late-Breaker Discussion: The AEGIS-II Trial Watch now
Late-Breaker Discussion: The RELIEVE-HF Trial Watch now
Late-Breaker Discussion: The ARISE-HF Trial Watch now

Part 3

Expert Interviews

Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

12 sessions
Gamification and Financial Incentives to Increase PA Among Patients at Elevated Cardiovascular Risk Watch now
Zilbesiran in Patients With Hypertension: KARDIA-2 Watch now
Olezarsen in Adults with Hypertriglyceridemia and ASCVD and/or Severe Hypertriglyceridemia Watch now
Lerodalcibep in Patients With High Risk For Cardiovascular Disease on Stable Lipid-Lowering Therapy Watch now
Chelation Therapy in Post-MI Pts with Diabetes: TACT2 Watch now
Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF Watch now
Self-Expanding vs Balloon Expandable TAVR: The SMART Trial Watch now
Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT Watch now
Technology-Assisted Nonprescription Rosuvastatin: TACTiC Watch now
Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC Watch now
TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6 Watch now
Periprocedural Cerebral Embolisms and Catheter Ablation of AF: The Embo-Abl Study Watch now

Part 4

Highlights

2 sessions
Artificial Intelligence in Cardiology: What You Need to Know in 2024 Watch now
Weight Loss Medications: What You Need to Know in 2024 Watch now

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

1 session
Coming Soon Watch now

About the episode

ACC.24 — We are joined by Dr Kengo Kusano (National Cerebral and Cardiovascular Center, JP) to discuss the findings from the Embo-Abl Study.

Embo-Abl is a multicenter prospective randomized study which aims to compare the incidence of periprocedural cerebral embolisms caused by catheter ablation of atrial fibrillation (AF) between cryoballoon and radiofrequency ablation. 230 patients with AF from a multicenter in Japan are included in this study, and were randomly assigned to either cryoballoon or radiofrequency ablation in a 1:1 fashion. The primary endpoint was the recurrence of MRI-detected silent cerebral events (SCE) 1-3 days after catheter ablation.

Findings showed that cryoballoon ablation demonstrated noninferiority as compared to radiofrequency ablation for the primary endpoint (risk difference, 4.18% [95% confidence interval, -4.18% to 12.5%]; P=0.02 for noninferiority). MES were higher with cryoballoon ablation as compared to radiofrequency ablation, however the number of MES, high-intensity transient signals and micro-bubbles during the cryoballoon ablation procedure were not associated with the incidence of cerebral embolisms.

Interview Questions:

  1. What is the importance of this study?
  2. What was the study design and patient population?
  3. What are the key findings?
  4. What is the potential impact of this study on clinical practice?
  5. What is the applicability of these results outside of Japan?
  6. What are your take-home messages?
  7. What further study is needed?

Recorded remotely from Atlanta, 2024.

Faculty Biographies

Kengo Kusano

Kengo Kusano

Director, Department of Cardiovascular Medicine

Dr. Kusano is the Chief Director of Department of Cardiovascular Medicine and also the Director of Division of Arrhythmia and Electrophysiology at National Cerebral and Cardiovascular Center, Osaka, Japan. He is also the affiliate professor of Okayama and Kumamoto University. His medical interest is cardiac clinical electrophysiology (devices, catheter ablation, inherited arrhythmias and cardiac sarcoidosis) as well as regenerative medicine using gene and cell therapy. He has published over 300 papers in peer-reviewed journals. After receiving his medical degree from Okayama University Medical School, he completed his cardiology training at the National Cardiovascular Center. He has delegated Japanese Ablation (J-AB) registry, Japanese Lead Extraction (J-LEX) registry and Japanese Left Atrial Appendage Occlusion (J-LAAO) registry with JHRS and JCS.

Dr Kengo Kusano is a member of the editorial board for the Journal of Asian Pacific Society of Cardiology,&nbsp…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.